TY - JOUR
T1 - Bioprosthetic valve fracture
T2 - Predictors of outcome and follow-up. Results from a multicenter study
AU - Brinkmann, Christina
AU - Abdel-Wahab, Mohamed
AU - Bedogni, Francesco
AU - Bhadra, Oliver D.
AU - Charbonnier, Gaetan
AU - Conradi, Lenard
AU - Hildick-Smith, David
AU - Kargoli, Faraj
AU - Latib, Azeem
AU - Van Mieghem, Nicolas M.
AU - Miura, Mizuki
AU - Mylotte, Darren
AU - Landes, Uri
AU - Pilgrim, Thomas
AU - Riess, Friedrich Christian
AU - Taramasso, Maurizio
AU - Tchétché, Didier
AU - Testa, Luca
AU - Thiele, Holger
AU - Webb, John
AU - Windecker, Stephan
AU - Witt, Julian
AU - Wohlmuth, Peter
AU - Wolf, Alexander
AU - Schofer, Joachim
N1 - Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2021/10
Y1 - 2021/10
N2 - Objectives: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). Background: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing. Methods: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers. Results: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients. Conclusions: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.
AB - Objectives: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR). Background: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing. Methods: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers. Results: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients. Conclusions: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.
KW - aortic valve disease
KW - percutaneous intervention
KW - percutaneous valve therapy
KW - structural heart disease intervention
KW - transcatheter valve implantation
UR - http://www.scopus.com/inward/record.url?scp=85105907942&partnerID=8YFLogxK
U2 - 10.1002/ccd.29755
DO - 10.1002/ccd.29755
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33991385
AN - SCOPUS:85105907942
SN - 1522-1946
VL - 98
SP - 756
EP - 764
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 4
ER -